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Abstract
Background: L-thyroxine (L-T4) malabsorption is a potential concern in patients with autoimmune atrophic
gastritis.
Methods: We evaluated five patients with autoimmune gastritis, who showed high serum thyrotropin (TSH) levels
(in the hypothyroid range) while in therapy with L-T4 in tablet. All patients were switched to receive an oral L-T4
liquid formulation maintaining the same dosage.
Results: In all patients who received L-T4 in tablet form after switching to an oral liquid formulation with the same
L-T4 dosage, TSH circulating levels were normalized. In four patients who were switched back again to receive L-T4
in tablets, maintaining the dosage, TSH levels worsened again reaching levels in the hypothyroid range.
Conclusions: The fact that the change from tablets to liquid oral formulation normalised serum TSH levels, and
that switching back to tablets caused thyrotropin levels to worsen, leads us to believe that absorption of L-T4 is
greater with oral liquid formulations in these patients. These results suggest that the L-T4 oral liquid formulation
could circumvent the pH alteration resulting from atrophic gastritis.
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Background
Thyroxine is absorbed through the intestinal mucosa at
the level of the jejunum and ileum. Intestinal absorption
of thyroxine is influenced by several factors, including the
age of the patient, adherence to therapy, dietary habits, ab-
sorption kinetics, malabsorption, and interference of other
drugs. The role of an acidic environment in thyroxine
absorption has been shown [1], even if gastric acid sup-
pression is inconsistently reported to interfere with
levothyroxine (L-T4) absorption [2]. The normally acid
environment of the stomach becomes altered in patients
with gastritis related to Helicobacter pylori infection, atro-
phic gastritis of the body of the stomach, or both [3, 4].
Recently, Centanni et al. showed that the daily re-
quirement of thyroxine was higher (by 22 to 34 %) in
patients with H. pylori-related gastritis, atrophic gas-
tritis, or both conditions than in the reference group,
in patients with multinodular goiter. These results
strongly suggest that normal gastric acid secretion is
necessary for the effective absorption of oral
thyroxine [5, 6]. It is well known that autoimmune
thyroiditis and gastritis are frequently associated [7].
Furthermore, it has been shown that L-T4 require-
ment in patients with autoimmune hypothyroidism
and parietal cell antibodies is increased [8].
For the therapy of hypothyroidism, L-T4 is used
worldwide in tablet form, but more recently new L-T4
formulations in soft gel capsule or liquid vials have
become available [6, 7].
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A recent report has shown an increased absorption
rate with liquid L-T4 formulation as opposed to tablet
form even in patients without malabsorption [9].
Furthermore, it has been shown that the liquid L-T4 is
able to solve tablet L-T4 malabsorption in patients who
underwent bariatric surgery [10].
However, until now, to the best of our knowledge, no
data are present in literature about the effectiveness of
a L-T4 liquid formulation in patients with autoimmune
gastritis.
Here we report that a new L-T4 liquid formulation
is able to normalize serum thyrotropin (TSH) levels
in hypothyroid patients in treatment with L-T4 in
tablets.
Methods
We report the results of a retrospective study. Ini-
tially we observed, one patient with autoimmune atro-
phic gastritis with an increase in serum TSH levels
while receiving L-T4 in tablet form. This condition
was reversibly resolved by switching to the same dose
in a liquid oral formulation. We subsequently identi-
fied four additional hypothyroid patients with auto-
immune atrophic gastritis, with high TSH while
receiving L-T4 tablets.
On the whole we evaluated five patients with auto-
immune gastritis, who showed high serum TSH
levels (in the hypothyroid range) while in therapy
with L-T4 in tablet.
All patients were switched to receive an oral L-T4
liquid formulation maintaining the same dosage.
In all patients TSH, free triiodothyronine (FT3), free
thyroxine (FT4) were re-evaluated after 1–2 months
from the switch from tablet to liquid L-T4.
Subsequently four patients were switched back again
from liquid L-T4 to receive L-T4 in tablets, maintaining
the dosage, and TSH, FT3, FT4 were re-evaluated after
2 months from the switch.
Since the liquid L-T4 formulation resulted in a better
control of TSH levels, all five patients were finally
treated with the liquid L-T4, and TSH, FT3, FT4 were
evaluated again after 6 months.
Serum FT4 (normal range, 0.8–1.7 ng/dL), FT3 (nor-
mal range, 2.3–4.2 pg/mL), and serum TSH (normal
range, 0.3–3.5 μIU/mL) were determined in all samples
by electrochemiluminescence immunoassay (Roche
Corporation, Indianapolis, IN, USA). The concentra-
tion of each hormone at baseline, and after the switch,
was calculated as a mean of the two samples collected
before the L-T4 dose.
The study was approved by the local Ethical Committee.
Each patient gave a written consent for participation in
the study, and gave consent for publication of these data.
Results
Patient 1 was a woman who was receiving stable
substitutive therapy for hypothyroidism due to
Hashimoto’s thyroiditis. In December 2011 she was
euthyroid receiving 110 μg L-T4 daily in tablet form,
ingested 30 min before breakfast. One year later, she
was about the same body weight, but her thyroid
hormone profile revealed subclinical hypothyroidism.
She did not receive any other therapy.
For the presence of persistent and severe dyspsepsia, she
underwent a gastroenterological examination that showed
the presence of high levels of gastrin (435 pg/mL), and of
increased levels of serum parietal cells antibodies, in
presence of atrophic gastritis (at gastroscopy), while the
search for H. pylori or H. pylori antibodies was negative.
We changed the formulation from oral tablets to the
liquid formulation, maintaining the same dosage. After
1 month, her TSH levels were in the normal range and
she felt better. To confirm the presumed relationship
between oral formulation and TSH normalisation, L-T4
was re-administered at the same dosage in tablet form.
Once again, serum TSH increased (Table 1). The
patient verified medication compliance.
Patient 2 The patient was a woman with
hypothyroidism due to previous radioiodine treatment
for Graves’ disease in 2010. After one year from
radioiodine, her thyroid hormone profile revealed
subclinical hypothyroidism. In March 2011 she started
treatment with L-T4 125 μg/daily in tablet form,
ingested 30 min before breakfast and in this way, she
became euthyroid, and remained euthyroid with the
same dosage for about 2 years. In August 2013 she
experienced post-prandial dyspepsia. The presence of
H. pylori antigen in the stool was negative. She was
then submitted to esophagus gastroscopy that showed
the presence of atrophic gastritis. In December 2013
with the same L-T4 dosage, her thyroid hormone
profile revealed subclinical hypothyroidism; she did not
receive any other therapy. In January 2014 we changed
the formulation from oral tablets to the liquid formulation,
maintaining the same dosage. After 2 months, her
TSH levels were in the normal range and she felt
better. To confirm the presumed relationship between
oral formulation and TSH normalisation, L-T4 was
re-administered at the same dosage in tablet form.
Once again, serum TSH increased (Table 1).
Patient 3 was a woman who was receiving stable
substitutive therapy for hypothyroidism due to
Hashimoto’s thyroiditis. In January 2013 she was
euthyroid receiving 100 μg L-T4 daily in tablet form,
ingested 30 min before breakfast. One year later, she
was the same body weight, but her thyroid hormone
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profile revealed subclinical hypothyroidism. She did not
receive any other therapy. She experienced post
prandial dyspepsia. The presence of H. pylori antigen in
the stool and of H. pylori antibodies was negative. She
was then submitted to esophagus gastroscopy that
showed the presence of atrophic gastritis. The patient
had also high levels of gastrin (556 pg/mL), and
increased levels of serum parietal cells antibodies.
We changed the formulation from oral tablets to the
liquid formulation, maintaining the same dosage. After
1 month, her TSH levels were in the normal range and
she felt better. To confirm the presumed relationship
between oral formulation and TSH normalisation, L-T4
was re-administered at the same dosage in tablet form.
Once again, serum TSH increased (Table 1). The
patient verified medication compliance.
Patient 4 was a woman who was receiving stable
substitutive therapy for hypothyroidism due to
Hashimoto’s thyroiditis. In December 2012 she was
euthyroid receiving 150 μg L-T4 daily in tablet
form, ingested 30 min before breakfast. One year
later, she was about the same body weight, but her
thyroid hormone profile revealed subclinical
hypothyroidism. She did not receive any other therapy.
For the presence of persistent and severe dyspsepsia
she underwent a gastroenterological examination and
esophagus gastroscopy that showed the presence of
increased levels of serum parietal cells antibodies, in
the presence of atrophic gastritis (search for H. pylori
or H. pylori antibodies was negative).
We changed the formulation from oral tablets to the
liquid formulation, maintaining the same dosage. After
2 months, her TSH levels were in the normal range
and she felt better. To confirm the presumed
relationship between oral formulation and TSH
normalisation, L-T4 was re-administered at the same
dosage in tablet form. Once again, serum TSH
increased (Table 1). The patient verified medication
compliance.
Patient 5 was a male, operated in 2005 with total
thyroidectomy for papillary thyroid cancer (PTC) (pT3,
N0, M0), and subsequently treated with radioiodine. A
recombinant human thyroid-stimulating hormone
(rhTSh) test in 2006 was negative for recurrence of
PTC. From 2008 to February 2011, with a stable dosage
of L-T4 in tablets (150 μg/day), TSH was suppressed
(< 0.001 μIU/mL), with normal FT4 and FT3 levels. For
the presence of persistent dyspepsia in November 2011,
he was then submitted to esophagus-gastroscopy that
showed the presence of autoimmune atrophic gastritis.
The presence of H. pylori antigen in the stool was nega-
tive. In July 2012 at the endocrinological control, TSH
levels were high, in presence of low circulating levels of
FT4, and FT3. The L-T4 tablet dosage was gradually
increased (from 150 to 250 μg/day L-T4) without a
significant correction of hypothyroidism. In November
2012 we changed the formulation from oral tablets to
the liquid L-T4, maintaining the same dosage. After
1 month, his TSH levels were in the normal range and
he felt better; after 2 months, TSH was suppressed, and
Table 1 Thyroid parameters with L-1 T4 tablets, with liquid L-T4 formulation, after switching back to L-T4 tablets, and after 6 months
of liquid L-T4 therapy
TabletL-T4 LiquidL-T4 TabletL-T4 LiquidL-T4
L-T4 TSH FT4 FT3 L-T4 TSH FT4 FT3 L-T4 TSH FT4 FT3 TSH
μgtablet μIU/mL ng/dL pg/mL μgliquid(months) μIU/mL ng/dL pg/mL μgtablet(months) μIU/mL ng/dL pg/mL μIU/mL
1 110 9.11 1.37 2.64 110 3.29 1.40 2.85 110 6.31 1.15 2.43 2.17
– – – – (1) – – – (2) – – – –
2 125 7.8 1.12 2.86 125 4.01 1.23 2.91 125 7.23 1.02 2.76 3.25
– – – – (2) – – – (2) – – – –
3 100 6.7 1.27 2.34 100 2.12 1.32 2.66 100 4.12 1.55 2.56 1.72
– – – – (1) – – – (2) – – – –
4 150 8.2 0.97 2.51 150 3.15 1.21 3.12 150 5.67 0.94 2.48 2.46
– – – – (2) – – – (2) – – – –
5 250 60 0.5 – 250 – – – – – – – –
– – – – (1) 3.8 1.19 2.74 – – – – 0.04
– – – – 200 – – – – – – – –
– – – – (2) 0.05 1.50 2.83 – – – – –
TSH, normal range 0.3–3.5 μIU/mL; FT4, normal range 0.8–1.7 ng/dL; FT3, normal range 2.3– 4.2 pg/mL
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it remained stably suppressed in the subsequent
controls.
All patients were finally treated with liquid L-T4, with a
good control of TSH values after 6 months of liquid
L-T4 therapy (Table 1).
Discussion
The gold standard replacement therapy for patients with
hypothyroidism is levothyroxine. There are requisites to
obtain an effective therapy, that are L-T4 products of opti-
mal quality [11], patients’ compliance [12], dissolution of
the hormone in the stomach [13], adequate absorption in
the intestines [5, 14], and normal metabolism [15]. Several
diseases and drugs affect the absorption and metabolism
of L-T4 [1]. Gastritis causes L-T4 malabsorption, by alter-
ing the gastric juice pH, thereby affecting L-T4 tablet
dissolution [8, 16, 17]. Recent studies have shown that
vitamin C improves circulating concentrations of TSH,
FT4, and total T3 in patients with gastritis and
hypothyroidism receiving L-T4 replacement therapy in
tablets, probably by increasing solubility of L-T4 in the
stomach [18, 19].
In fact, normal gastric acid secretion is necessary for
effective absorption of L-T4 [5] by dissolution of tablets,
and drug dissolution and solubility may be altered by re-
strictive procedures that increase gastric pH in the newly
created stomach pouch; this may occur in gastric bypass
[20]. However a recent report has shown that the liquid
L-T4 is able to solve tablet L-T4 malabsorption in
patients who underwent bariatric surgery [10].
It has been also shown that the liquid formulation of
L-T4 is extremely effective to circumvent the problem of
incomplete absorption of the L-T4 caused by proton
pump inhibitors [21].
Here, we report normalisation of serum TSH levels in
five patients with atrophic gastritis who received L-T4 in
tablet form after switching to an oral liquid formulation.
In four patients switching back to tablets caused
thyrotropin levels to worsen. The fact that the change
from tablets to liquid oral formulation normalised serum
TSH levels, and that switching back to tablets caused
thyrotropin levels to worsen, in absence of any change
of L-T4 dosage, leads us to believe that absorption of
thyroxine is greater with oral liquid formulations in
these patients; the involved mechanisms need to be fur-
ther studied.
Previous pharmacokinetics studies with liquid L-T4
have shown a clearly faster onset of absorption, compared
to tablets (area under the curve from 0 to 2 h greater than
50 %; time to maximum concentration faster by a mean of
30 min), as consequence that liquid formulation does not
need gastric dissolution, and enters directly the small
bowel where L-T4 is absorbed [22–25].
However the presence of alcohol in the L-T4 liquid
formulation could also play a key role in thyroxine ab-
sorption. Indeed, oral mucosal is highly vascularised, and
drugs that are absorbed through the oral mucosal dir-
ectly enter the systemic circulation, bypassing the
gastrointestinal tract [26]. Additional studies are needed
to clarify this interesting point.
Conclusions
These results suggest that the L-T4 oral liquid formula-
tion could circumvent the pH alteration resulting from
atrophic gastritis [6].
It is likely that patients affected by condition that im-
pairs L-T4 absorption (e.g., atrophic gastritis, H. pylori
infection and proton-pump inhibitors) could benefit from
a liquid formulation.
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